SlideShare a Scribd company logo
DIABETES IN
PREGNANCY
Pre-existing DM
Gestational diabetes
Diabetes in
pregnancy
Pre-existing
diabetes
IDDM
(Type1)
NIDDM
(Type2)
Gestational
diabetes
Pre-existing
diabetes
True GDM
 Gestational diabetes (GDM) is defined as any degree
of impaired glucose tolerance of with onset or first
recognition during pregnancy .
 Many are denovo pregnancy induced
 Some are type 2 ( 35-40%)
 10% have antibodies
 Difficult to distinguish pregestational Type 2 DM and denovo
GDM
 Fasting hyperglycemia
 blood glucose greater than 200 mg/dL on OGT
 acanthosis nicgrans
 HbA1C > 6%
 a systolic BP > 110 mm Hg
 BMI > 30 kg/m2
 Fetal anomalies
 Clues for Type 1
 Lean
 DKA during pregnancy
 Severe hyperglycemia requiring large doses of insulin
Fuel metabolism in pregnancy
 Goal is uninterrupted nutrient supply to fetus
 The metabolic goals of pregnancy are
 1) in early pregnancy to develop anabolic stores to meet
metabolic demands in late pregnancy
 2) in late pregnancy to provide fuels for fetal growth and
energy needs.
Glucose metabolism in pregnancy
 Early pregnancy
 E2/PRL stimulates b cells –Insulin sensitivity same and
peripheral glucose utilisation – 10% fall in BG levels
 Late pregnancy
 Fetoplacental unit extracts glucose and aminoacids, fat is
used mainly for fuel metabolism
 Insulin sensitivity decreases progressively upto 50-80%
during the third trimester
 variety of hormones secreted by the placenta, especially
hPL and placental growth hormone variant, cortisol,
PRL,E2 and Prog
Glucose metabolism in pregnancy
Fetus
Fat
Glucose Aminoacids
Insulin Hyperins
ulinemia
FASTING
accelerated
starvation and
exaggerated ketosis
(maternal
hypoglycemia,
hypoinsulinemia,
hyperlipidemia, and
hyperketonemia)
FED
hyperglycemia,
hyperinsulinemia,
hyperlipidemia,
and reduced tissue
sensitivity to
insulin
RISK FACTORS
 History of macrosomia:birth weght>4 Kg,h/o GDM previous
pregnancy
 Race
 Polycystic ovarian syndrome
 Essential hypertension or pregnancy-related hypertension
 history of spontaneous abortions and unexplained stillbirths
 strong family history of diabetes (especially in first-degree
relatives)
 obesity ( [BMI] > 30)
 age older than 25 years
 persistent glucosuria
 “NO KNOWN RISK FACTORS IN 50% OF GDM”
 ADA recommends selective screening for GDM, but
according to indian guidelines we follow universal
screening
Maternal complications
 Worsening retinopathy – 10% new DR, 20% mild NPDR and
55% mod-severe NPDR progresses
 Worsening proteinuria. GFR decline depends on
preconception creatinine and proteinuria
 Hypertension and Cardiovascular disease
 Neuropathy – No worsening (gastroparesis, nausea,
orthostatic dizziness can be worsened)
 Infection
 Fetal:
 Congenital abnormalities
 Increased neonatal and perinatal mortality
 Macrosomia
 Late stillbirth
 Neonatal hypoglycemia
 Polycythemia
 jaundice
SCREENING AND DIAGNOSIS
Diagnosis of GDM
 The WHO 1999 criteria.
 Introduced in 1999.
 Glucose load is 75g.
 GDM diagnosed if the plasma glucose is 140mg /dl or
above 2 hours after the glucose load.
 In 2013 ,WHO dropped in own 1999 criteria and
accepted the IADPSG criteria.
IADPSG guidelines
 Screening for GDM.
 Performed at 24 to 28 weeks of gestation.
 75g two hour OGTT is used.
 GDM is diagnosed if any one value exceeds the
thresholds shown below.
 fasting 1hr 2hr
 Plasma glucose ≥92 ≥180 ≥153
 (mg/dl)
Whom and when to screen? Indian
Scenario - The DIPSI Guidelines
 75 gm GCT with single PG at 2 hrs –
 ≥ 140 mg/dL is GDM
 ≥ 120 mg/dL is DGGT
 >200mg/dl is diabetes
 Universal screening
 First trimester, if negative at 24 – 28 weeks and then at 32 – 34
weeks
Why in India,separate guidelines for
screening?
 Indian females-11 fold increased risk of GDM than
Caucasians.
 Prevalence is 16.55%
 Universal screening detects more number of GDM.
 Single blood glucose measurement after
GCT,economically feasible,more patient compliance.
MANAGEMENT
MANAGEMENT ISSUES
 Patient education
 Medical Nutrition therapy
 Pharmacological therapy
 Glycemic monitoring: SMBG and targets
 Fetal monitoring: ultrasound
 Planning on delivery
 If FPG >120,start insulin
 Others:Advise MNT,3 days of SMBG,fasting,and 3 one and
half hour post prandial blood glucose.
 After MNT,1-2 weeks,start insulin if majority of fasting
ie,four-seven >90
 Or majority of any one of PP >120
Medical nutrition therapy
 Goals
 Achieve normoglycemia
 Prevent ketosis
 Provide adequate weight gain
 Contribute to fetal well-being
 Nutritional plan
 Calorie allotment
 Calorie distribution
 CH2O intake
Calorie allotment
 30 kcal per kg current weight per day in pregnant women
who are BMI 22 to 25.
 24 kcal per kg current weight per day in overweight
pregnant women (BMI 26 to 29).
 12 to 15 kcal per kg current weight per day for morbidly
obese pregnant women (BMI >30).
 40 kcal per kg current weight per day in pregnant women
who are less than BMI 22.
 Postprandial blood glucose concentrations can be
blunted if the diet is carbohydrate restricted. Complex
carbohydrates, such as those in starches and
vegetables, are more nutrient dense and raise
postprandial blood glucose concentrations less than
simple sugars.
 Carbohydrate intake is restricted to 33-40% of calories,
with the remainder divided between protein (about 20%)
and fat (about 40%).
 With this calorie distribution, 75 to 80 percent of women
with GDM will achieve normoglycemia.
Calorie distribution
 Variable opinion
 Most programs suggest three meals and three snacks;
however, in overweight and obese women the snacks are
often eliminated
 Breakfast — The breakfast meal should be small
(approximately 10%of total calories) to help maintain
postprandial euglycemia. Carbohydrate intake at
breakfast is also limited since insulin resistance is
greatest in the morning.
 Lunch — 30% of total calories
 Dinner — 30% of total calories
 Snacks — Leftover calories (approximately 30% of total
calories) are distributed, as needed, as snacks.
Diabetes in Pregnancy: Physical Activity
 Unless contraindicated, physical activity should be
included in a pregnant woman’s daily regimen
 Regular moderate-intensity physical activity (eg, walking)
can help to reduce glucose levels in patients with GDM
 Other appropriate forms of exercise during pregnancy
 Cardiovascular training with weight-bearing, limited to the upper
body to avoid mechanical stress on the abdominal region
Monitoring BG
 Atleast 4 times-self monitoring
 Fasting and 3 one and half hour postprandial
 After achieving target level,lab monitoring till 28 weeks
once in a month
 28-32 weeks once in 2 weeks
 >32 once a week
 Other parameters to be monitored:fundus,micro
albuminuria
Glycemic targets
 Mean plasma glucose of 105 mg/dl
 Achieved by maintaining FPG at 90 & PP at 120
 Mean plasma glucose should never go below 86
INSULIN THERAPY
 Type of insulin used-always human insulin or analogues
 In India,basal insulin is usually given as NPH.
 Basal may be provided with long acting or intermediate acting
or continuos infusion
 Insulin for post prandial control-short acting(regular or
analogue)
 NPH-intermediate acting-category B
 Detemir-long acting category B
 Lispro,aspar ultra short acting-category B
 Glargine-long acting-category C
INSULIN THERAPY
 NPH is usually started at 4 units and then titrated
 If morning PP is more,regular insulin in morning
 If predinner is high,night dose of rapid insulin
 Mixed split regimen-total insulin requirement-2/3 in
morning,1/3 night,of each dose 1/3 rapid and 2/3
intermediate acting.
Insulin
 ≈ 15% need insulin
 Total dose varies. ≈ 0.7 to 2 units per kilogram (present pregnant
weight)
 FBG high – Night NPH ≈ 0.2 units/kg
 PPBG high – bolus ≈ 1.5 units/10 gm CH2O for breakfast and ≈ 1
unit /10 gm CH2O for lunch and dinner
 If both pre and postprandial BG high or if the woman's
postprandial glucose levels can only be blunted if starvation
ketosis occurs - four injection/day regimen.
 Total 0.7 unit/kg up to week 18
 0.8 unit/kg for weeks 18 to 26
 0.9 unit/kg for weeks 26 to 36
 1. unit/kg for weeks 36 to term.
 In a morbidly obese woman, the initial doses of insulin may need to
be increased to 1.5 to 2. units/kg to overcome the combined insulin
resistance of pregnancy and obesity.
Status of OHA in pregnancy
 Metformin and the sulfonylurea glyburide are the 2 most commonly
prescribed oral antihyperglycemic agents during pregnancy
 Due to efficacy and safety concerns, the ADA and DIPSI does not
recommend oral antihyperglycemic agents for gestational diabetes mellitus
(GDM) or preexisting T2DM
Medication Crosses
Placenta
Classification Notes
Metformin Yes Category B Metformin and glyburide may be
insufficient to maintain normoglycemia at
all times, particularly during postprandial
period
Glyburide Minimal
transfer
Some formulations
category B, others
category C
Fetal monitoring
 USG:18-20 weeks,anomaly scan
 Fetal ECHO:20-24 weeks
 From 26 weeks,every 2-3 weeks-liquor volume
 Abdominal circumference monitoring>70 indication of
insulin
 Chromosomal abnormalities,NTD
Management Intrapartum
 Attention to labor pattern, as cephalopelvic disproportion may
indicate fetal macrosomia
 If steroids or beta agonists used,increase insulin
 Skip morning insulin on day of induction.
 Usually no need of insulin while labour.
 Hourly blood glucose monitoring during active labor, with
insulin drip if necessary
 Notify pediatrics if patient has poorly controlled blood sugars
antepartum or intrapartum
Management Postpartum
 For patients with pregestational diabetes, halve dose of
insulin and continue to check blood glucose in immediate
postpartum period
 For GDM patients who required insulin therapy (GDMA2),
check fasting and postprandial blood sugars and treat with
insulin as necessary
 For GDM patients who were diet controlled (GDMA1), no
further monitoring nor therapy is necessary immediately
postpartum
 Metformin and glyburide are secreted into breast milk and are
therefore contraindicated during lactation
 Breastfeeding plus insulin therapy may lead to severe
hypoglycemia1
 Greatest risk is in women with T1DM
 Preventive measures are: reduce basal insulin dosage and/or
carbohydrate intake prior to breastfeeding
 For baby,start early breast feeding,CBG at 1 hour and 4 values in
first 24 hours,before each feed.<44 is considered hypoglycemia.
Management Postpartum
 For all GDM patients, perform 75 gram 2-hour OGTT
at 6 week postpartum visit to rule out pregestational
diabetes
 Most common recommendation is for primary care
physician to repeat
 2-hour OGTT every three years
Who will progress to DM?
 WC and BMI – stronset predictors
 Autoantibodies
 DM at earlier gestational age
 Gestational requirement of insulin
 Higher FBG
 Higher BG on OGTT
 Neonatal hypoglycemia
 Recurrent GDM
Thank You

More Related Content

What's hot

Antepartum haemorrhage
Antepartum haemorrhageAntepartum haemorrhage
Antepartum haemorrhageHui Pheng Neoh
 
Postpartum hemorrhage
Postpartum hemorrhage Postpartum hemorrhage
Postpartum hemorrhage
Anamika Ramawat
 
Obstructed labour
Obstructed labourObstructed labour
Obstructed labour
Naila Memon
 
Anaemia in pregnancy
Anaemia in pregnancyAnaemia in pregnancy
Anaemia in pregnancy
Bharati vidyapeeth university
 
Hypertension in pregnancy
Hypertension in pregnancyHypertension in pregnancy
Hypertension in pregnancy
Rashna Sharmin
 
HIV In Pregnancy
HIV In Pregnancy HIV In Pregnancy
HIV In Pregnancy
jayatheeswaranvijayakumar
 
Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)
Summu Thakur
 
Breech presentation
 Breech presentation Breech presentation
Breech presentation
obgymgmcri
 
Partograph
PartographPartograph
Partograph
Shrooti Shah
 
Multiple pregnancy
Multiple pregnancyMultiple pregnancy
Multiple pregnancyFahad Zakwan
 
Rupture of the uterus
Rupture of the uterusRupture of the uterus
Rupture of the uterusFahad Zakwan
 
Gestational hypertension
Gestational hypertensionGestational hypertension
Gestational hypertension
University of Florida
 
Hyperemesis gravidarum
Hyperemesis gravidarumHyperemesis gravidarum
Hyperemesis gravidarum
jagadeeswari jayaseelan
 
Induction and augmentation of labour
Induction and augmentation of labourInduction and augmentation of labour
Induction and augmentation of labour
imanswati
 
Breech presentation
Breech presentationBreech presentation
Breech presentationraj kumar
 
Oligohydramnios
OligohydramniosOligohydramnios
Oligohydramnios
Sharon Treesa Antony
 
Shoulder dystocia
Shoulder dystociaShoulder dystocia
Shoulder dystocia
Shrooti Shah
 

What's hot (20)

Pph
PphPph
Pph
 
Antepartum haemorrhage
Antepartum haemorrhageAntepartum haemorrhage
Antepartum haemorrhage
 
Postpartum hemorrhage
Postpartum hemorrhage Postpartum hemorrhage
Postpartum hemorrhage
 
Obstructed labour
Obstructed labourObstructed labour
Obstructed labour
 
Anaemia in pregnancy
Anaemia in pregnancyAnaemia in pregnancy
Anaemia in pregnancy
 
Pih
PihPih
Pih
 
Hypertension in pregnancy
Hypertension in pregnancyHypertension in pregnancy
Hypertension in pregnancy
 
HIV In Pregnancy
HIV In Pregnancy HIV In Pregnancy
HIV In Pregnancy
 
Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)Intrauterine growth retardation (IUGR)
Intrauterine growth retardation (IUGR)
 
Breech presentation
 Breech presentation Breech presentation
Breech presentation
 
Partograph
PartographPartograph
Partograph
 
Multiple pregnancy
Multiple pregnancyMultiple pregnancy
Multiple pregnancy
 
Rupture of the uterus
Rupture of the uterusRupture of the uterus
Rupture of the uterus
 
Gestational hypertension
Gestational hypertensionGestational hypertension
Gestational hypertension
 
Prom
PromProm
Prom
 
Hyperemesis gravidarum
Hyperemesis gravidarumHyperemesis gravidarum
Hyperemesis gravidarum
 
Induction and augmentation of labour
Induction and augmentation of labourInduction and augmentation of labour
Induction and augmentation of labour
 
Breech presentation
Breech presentationBreech presentation
Breech presentation
 
Oligohydramnios
OligohydramniosOligohydramnios
Oligohydramnios
 
Shoulder dystocia
Shoulder dystociaShoulder dystocia
Shoulder dystocia
 

Similar to Gestational diabetes mellitus

gdm (1).pptx
gdm (1).pptxgdm (1).pptx
gdm (1).pptx
AnithaAldur
 
gdm (1).pptx
gdm (1).pptxgdm (1).pptx
gdm (1).pptx
AnithaAldur
 
GDM_ Dr Selim
GDM_ Dr SelimGDM_ Dr Selim
Gestational Diabetes by Dr Shahjada Selim
Gestational Diabetes by Dr Shahjada SelimGestational Diabetes by Dr Shahjada Selim
Gestational Diabetes by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
An update on gdm management
An update on gdm managementAn update on gdm management
An update on gdm management
namkha dorji
 
Diabetes in Pregnancy
Diabetes in PregnancyDiabetes in Pregnancy
Diabetes in Pregnancy
Shashikiran Umakanth
 
Gestational Diabetes Mellitus.pptx
Gestational Diabetes Mellitus.pptxGestational Diabetes Mellitus.pptx
Gestational Diabetes Mellitus.pptx
susanta12
 
Gestational diabetes mellitus
Gestational diabetes mellitusGestational diabetes mellitus
Gestational diabetes mellitusdr hina khudaidad
 
Diabetes+and+Pregnancy
Diabetes+and+PregnancyDiabetes+and+Pregnancy
Diabetes+and+Pregnancydhavalshah4424
 
Diabetes In Pregnancy
Diabetes In PregnancyDiabetes In Pregnancy
Diabetes In Pregnancy
Sabah Salim
 
GDM_ gestational diabetes mellitus : gynecology & obstetrics
GDM_ gestational diabetes mellitus : gynecology & obstetricsGDM_ gestational diabetes mellitus : gynecology & obstetrics
GDM_ gestational diabetes mellitus : gynecology & obstetrics
SamraEjaz1
 
Pregestational Diabetes in pregnancy
Pregestational Diabetes in pregnancyPregestational Diabetes in pregnancy
Pregestational Diabetes in pregnancy
Sujoy Dasgupta
 
Diabetes mellitus in pregnancy
Diabetes mellitus in pregnancyDiabetes mellitus in pregnancy
Diabetes mellitus in pregnancyPrativa Dhakal
 
Hypoglycemia Hyperglycemia In The Pregnant Patient
Hypoglycemia Hyperglycemia In The Pregnant PatientHypoglycemia Hyperglycemia In The Pregnant Patient
Hypoglycemia Hyperglycemia In The Pregnant Patient
Kelly Miller
 
Diabetes&pregnancy
Diabetes&pregnancyDiabetes&pregnancy
Diabetes&pregnancydrmcbansal
 
Gestational Diabetes Mellitus
Gestational Diabetes MellitusGestational Diabetes Mellitus
Gestational Diabetes Mellitus
Niranjan Chavan
 
Hypoglycemia and hyperglycemia in the pregnanat patient
Hypoglycemia and hyperglycemia in the pregnanat patientHypoglycemia and hyperglycemia in the pregnanat patient
Hypoglycemia and hyperglycemia in the pregnanat patientKelly Miller
 
Gestational Diabetes Mellitus
Gestational Diabetes MellitusGestational Diabetes Mellitus
Gestational Diabetes Mellitus
sriharsha3690
 

Similar to Gestational diabetes mellitus (20)

gdm (1).pptx
gdm (1).pptxgdm (1).pptx
gdm (1).pptx
 
gdm (1).pptx
gdm (1).pptxgdm (1).pptx
gdm (1).pptx
 
GDM_ Dr Selim
GDM_ Dr SelimGDM_ Dr Selim
GDM_ Dr Selim
 
Gestational Diabetes by Dr Shahjada Selim
Gestational Diabetes by Dr Shahjada SelimGestational Diabetes by Dr Shahjada Selim
Gestational Diabetes by Dr Shahjada Selim
 
An update on gdm management
An update on gdm managementAn update on gdm management
An update on gdm management
 
Diabetes in Pregnancy
Diabetes in PregnancyDiabetes in Pregnancy
Diabetes in Pregnancy
 
Gestational Diabetes Mellitus.pptx
Gestational Diabetes Mellitus.pptxGestational Diabetes Mellitus.pptx
Gestational Diabetes Mellitus.pptx
 
Gestational diabetes mellitus
Gestational diabetes mellitusGestational diabetes mellitus
Gestational diabetes mellitus
 
Diabetes+and+Pregnancy
Diabetes+and+PregnancyDiabetes+and+Pregnancy
Diabetes+and+Pregnancy
 
Diabetes In Pregnancy[1]
Diabetes In Pregnancy[1]Diabetes In Pregnancy[1]
Diabetes In Pregnancy[1]
 
Diabetes In Pregnancy
Diabetes In PregnancyDiabetes In Pregnancy
Diabetes In Pregnancy
 
GDM_ gestational diabetes mellitus : gynecology & obstetrics
GDM_ gestational diabetes mellitus : gynecology & obstetricsGDM_ gestational diabetes mellitus : gynecology & obstetrics
GDM_ gestational diabetes mellitus : gynecology & obstetrics
 
GDM
GDMGDM
GDM
 
Pregestational Diabetes in pregnancy
Pregestational Diabetes in pregnancyPregestational Diabetes in pregnancy
Pregestational Diabetes in pregnancy
 
Diabetes mellitus in pregnancy
Diabetes mellitus in pregnancyDiabetes mellitus in pregnancy
Diabetes mellitus in pregnancy
 
Hypoglycemia Hyperglycemia In The Pregnant Patient
Hypoglycemia Hyperglycemia In The Pregnant PatientHypoglycemia Hyperglycemia In The Pregnant Patient
Hypoglycemia Hyperglycemia In The Pregnant Patient
 
Diabetes&pregnancy
Diabetes&pregnancyDiabetes&pregnancy
Diabetes&pregnancy
 
Gestational Diabetes Mellitus
Gestational Diabetes MellitusGestational Diabetes Mellitus
Gestational Diabetes Mellitus
 
Hypoglycemia and hyperglycemia in the pregnanat patient
Hypoglycemia and hyperglycemia in the pregnanat patientHypoglycemia and hyperglycemia in the pregnanat patient
Hypoglycemia and hyperglycemia in the pregnanat patient
 
Gestational Diabetes Mellitus
Gestational Diabetes MellitusGestational Diabetes Mellitus
Gestational Diabetes Mellitus
 

More from ikramdr01

MI LOCALISATION.pptx
MI LOCALISATION.pptxMI LOCALISATION.pptx
MI LOCALISATION.pptx
ikramdr01
 
atrial fibrillation 2020 guidelines
atrial fibrillation 2020 guidelinesatrial fibrillation 2020 guidelines
atrial fibrillation 2020 guidelines
ikramdr01
 
Wheezing dos and donts
Wheezing dos and dontsWheezing dos and donts
Wheezing dos and donts
ikramdr01
 
Imaging in stroke
Imaging in strokeImaging in stroke
Imaging in stroke
ikramdr01
 
arterial disorders
arterial disordersarterial disorders
arterial disorders
ikramdr01
 
interstitial lung diseases
interstitial lung diseasesinterstitial lung diseases
interstitial lung diseases
ikramdr01
 
Innovative gadgets in anesthesia and medicine
Innovative gadgets in anesthesia and medicine Innovative gadgets in anesthesia and medicine
Innovative gadgets in anesthesia and medicine
ikramdr01
 
Clinical cardiology
Clinical cardiologyClinical cardiology
Clinical cardiology
ikramdr01
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
ikramdr01
 
Gestational trophoblastic diseases
Gestational trophoblastic diseasesGestational trophoblastic diseases
Gestational trophoblastic diseases
ikramdr01
 
Heart failure
Heart failure Heart failure
Heart failure
ikramdr01
 
Scorpion sting
Scorpion stingScorpion sting
Scorpion sting
ikramdr01
 
Sarcoidosis and IgG4
Sarcoidosis and IgG4Sarcoidosis and IgG4
Sarcoidosis and IgG4
ikramdr01
 
Neuropathic pain understanding and management
Neuropathic pain understanding and managementNeuropathic pain understanding and management
Neuropathic pain understanding and management
ikramdr01
 
Optimizing heart failure management
Optimizing heart failure managementOptimizing heart failure management
Optimizing heart failure management
ikramdr01
 
Kawasaki disease
Kawasaki diseaseKawasaki disease
Kawasaki disease
ikramdr01
 
bedside approach to common congenital heart diseases
bedside approach to common congenital heart diseasesbedside approach to common congenital heart diseases
bedside approach to common congenital heart diseases
ikramdr01
 
Atrial fibrillation
Atrial fibrillation Atrial fibrillation
Atrial fibrillation
ikramdr01
 
Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
ikramdr01
 
Acute decompensated heart failure
Acute decompensated heart failure Acute decompensated heart failure
Acute decompensated heart failure
ikramdr01
 

More from ikramdr01 (20)

MI LOCALISATION.pptx
MI LOCALISATION.pptxMI LOCALISATION.pptx
MI LOCALISATION.pptx
 
atrial fibrillation 2020 guidelines
atrial fibrillation 2020 guidelinesatrial fibrillation 2020 guidelines
atrial fibrillation 2020 guidelines
 
Wheezing dos and donts
Wheezing dos and dontsWheezing dos and donts
Wheezing dos and donts
 
Imaging in stroke
Imaging in strokeImaging in stroke
Imaging in stroke
 
arterial disorders
arterial disordersarterial disorders
arterial disorders
 
interstitial lung diseases
interstitial lung diseasesinterstitial lung diseases
interstitial lung diseases
 
Innovative gadgets in anesthesia and medicine
Innovative gadgets in anesthesia and medicine Innovative gadgets in anesthesia and medicine
Innovative gadgets in anesthesia and medicine
 
Clinical cardiology
Clinical cardiologyClinical cardiology
Clinical cardiology
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Gestational trophoblastic diseases
Gestational trophoblastic diseasesGestational trophoblastic diseases
Gestational trophoblastic diseases
 
Heart failure
Heart failure Heart failure
Heart failure
 
Scorpion sting
Scorpion stingScorpion sting
Scorpion sting
 
Sarcoidosis and IgG4
Sarcoidosis and IgG4Sarcoidosis and IgG4
Sarcoidosis and IgG4
 
Neuropathic pain understanding and management
Neuropathic pain understanding and managementNeuropathic pain understanding and management
Neuropathic pain understanding and management
 
Optimizing heart failure management
Optimizing heart failure managementOptimizing heart failure management
Optimizing heart failure management
 
Kawasaki disease
Kawasaki diseaseKawasaki disease
Kawasaki disease
 
bedside approach to common congenital heart diseases
bedside approach to common congenital heart diseasesbedside approach to common congenital heart diseases
bedside approach to common congenital heart diseases
 
Atrial fibrillation
Atrial fibrillation Atrial fibrillation
Atrial fibrillation
 
Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
 
Acute decompensated heart failure
Acute decompensated heart failure Acute decompensated heart failure
Acute decompensated heart failure
 

Recently uploaded

Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 

Recently uploaded (20)

Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 

Gestational diabetes mellitus

  • 4.  Gestational diabetes (GDM) is defined as any degree of impaired glucose tolerance of with onset or first recognition during pregnancy .  Many are denovo pregnancy induced  Some are type 2 ( 35-40%)  10% have antibodies
  • 5.  Difficult to distinguish pregestational Type 2 DM and denovo GDM  Fasting hyperglycemia  blood glucose greater than 200 mg/dL on OGT  acanthosis nicgrans  HbA1C > 6%  a systolic BP > 110 mm Hg  BMI > 30 kg/m2  Fetal anomalies  Clues for Type 1  Lean  DKA during pregnancy  Severe hyperglycemia requiring large doses of insulin
  • 6. Fuel metabolism in pregnancy  Goal is uninterrupted nutrient supply to fetus  The metabolic goals of pregnancy are  1) in early pregnancy to develop anabolic stores to meet metabolic demands in late pregnancy  2) in late pregnancy to provide fuels for fetal growth and energy needs.
  • 7. Glucose metabolism in pregnancy  Early pregnancy  E2/PRL stimulates b cells –Insulin sensitivity same and peripheral glucose utilisation – 10% fall in BG levels  Late pregnancy  Fetoplacental unit extracts glucose and aminoacids, fat is used mainly for fuel metabolism  Insulin sensitivity decreases progressively upto 50-80% during the third trimester  variety of hormones secreted by the placenta, especially hPL and placental growth hormone variant, cortisol, PRL,E2 and Prog
  • 8. Glucose metabolism in pregnancy Fetus Fat Glucose Aminoacids Insulin Hyperins ulinemia FASTING accelerated starvation and exaggerated ketosis (maternal hypoglycemia, hypoinsulinemia, hyperlipidemia, and hyperketonemia) FED hyperglycemia, hyperinsulinemia, hyperlipidemia, and reduced tissue sensitivity to insulin
  • 9. RISK FACTORS  History of macrosomia:birth weght>4 Kg,h/o GDM previous pregnancy  Race  Polycystic ovarian syndrome  Essential hypertension or pregnancy-related hypertension  history of spontaneous abortions and unexplained stillbirths  strong family history of diabetes (especially in first-degree relatives)  obesity ( [BMI] > 30)  age older than 25 years  persistent glucosuria
  • 10.  “NO KNOWN RISK FACTORS IN 50% OF GDM”  ADA recommends selective screening for GDM, but according to indian guidelines we follow universal screening
  • 11. Maternal complications  Worsening retinopathy – 10% new DR, 20% mild NPDR and 55% mod-severe NPDR progresses  Worsening proteinuria. GFR decline depends on preconception creatinine and proteinuria  Hypertension and Cardiovascular disease  Neuropathy – No worsening (gastroparesis, nausea, orthostatic dizziness can be worsened)  Infection
  • 12.  Fetal:  Congenital abnormalities  Increased neonatal and perinatal mortality  Macrosomia  Late stillbirth  Neonatal hypoglycemia  Polycythemia  jaundice
  • 14. Diagnosis of GDM  The WHO 1999 criteria.  Introduced in 1999.  Glucose load is 75g.  GDM diagnosed if the plasma glucose is 140mg /dl or above 2 hours after the glucose load.  In 2013 ,WHO dropped in own 1999 criteria and accepted the IADPSG criteria.
  • 15. IADPSG guidelines  Screening for GDM.  Performed at 24 to 28 weeks of gestation.  75g two hour OGTT is used.  GDM is diagnosed if any one value exceeds the thresholds shown below.  fasting 1hr 2hr  Plasma glucose ≥92 ≥180 ≥153  (mg/dl)
  • 16. Whom and when to screen? Indian Scenario - The DIPSI Guidelines  75 gm GCT with single PG at 2 hrs –  ≥ 140 mg/dL is GDM  ≥ 120 mg/dL is DGGT  >200mg/dl is diabetes  Universal screening  First trimester, if negative at 24 – 28 weeks and then at 32 – 34 weeks
  • 17. Why in India,separate guidelines for screening?  Indian females-11 fold increased risk of GDM than Caucasians.  Prevalence is 16.55%  Universal screening detects more number of GDM.  Single blood glucose measurement after GCT,economically feasible,more patient compliance.
  • 19. MANAGEMENT ISSUES  Patient education  Medical Nutrition therapy  Pharmacological therapy  Glycemic monitoring: SMBG and targets  Fetal monitoring: ultrasound  Planning on delivery
  • 20.  If FPG >120,start insulin  Others:Advise MNT,3 days of SMBG,fasting,and 3 one and half hour post prandial blood glucose.  After MNT,1-2 weeks,start insulin if majority of fasting ie,four-seven >90  Or majority of any one of PP >120
  • 21. Medical nutrition therapy  Goals  Achieve normoglycemia  Prevent ketosis  Provide adequate weight gain  Contribute to fetal well-being  Nutritional plan  Calorie allotment  Calorie distribution  CH2O intake
  • 22. Calorie allotment  30 kcal per kg current weight per day in pregnant women who are BMI 22 to 25.  24 kcal per kg current weight per day in overweight pregnant women (BMI 26 to 29).  12 to 15 kcal per kg current weight per day for morbidly obese pregnant women (BMI >30).  40 kcal per kg current weight per day in pregnant women who are less than BMI 22.
  • 23.  Postprandial blood glucose concentrations can be blunted if the diet is carbohydrate restricted. Complex carbohydrates, such as those in starches and vegetables, are more nutrient dense and raise postprandial blood glucose concentrations less than simple sugars.  Carbohydrate intake is restricted to 33-40% of calories, with the remainder divided between protein (about 20%) and fat (about 40%).  With this calorie distribution, 75 to 80 percent of women with GDM will achieve normoglycemia.
  • 24. Calorie distribution  Variable opinion  Most programs suggest three meals and three snacks; however, in overweight and obese women the snacks are often eliminated  Breakfast — The breakfast meal should be small (approximately 10%of total calories) to help maintain postprandial euglycemia. Carbohydrate intake at breakfast is also limited since insulin resistance is greatest in the morning.  Lunch — 30% of total calories  Dinner — 30% of total calories  Snacks — Leftover calories (approximately 30% of total calories) are distributed, as needed, as snacks.
  • 25. Diabetes in Pregnancy: Physical Activity  Unless contraindicated, physical activity should be included in a pregnant woman’s daily regimen  Regular moderate-intensity physical activity (eg, walking) can help to reduce glucose levels in patients with GDM  Other appropriate forms of exercise during pregnancy  Cardiovascular training with weight-bearing, limited to the upper body to avoid mechanical stress on the abdominal region
  • 26. Monitoring BG  Atleast 4 times-self monitoring  Fasting and 3 one and half hour postprandial  After achieving target level,lab monitoring till 28 weeks once in a month  28-32 weeks once in 2 weeks  >32 once a week  Other parameters to be monitored:fundus,micro albuminuria
  • 27. Glycemic targets  Mean plasma glucose of 105 mg/dl  Achieved by maintaining FPG at 90 & PP at 120  Mean plasma glucose should never go below 86
  • 28. INSULIN THERAPY  Type of insulin used-always human insulin or analogues  In India,basal insulin is usually given as NPH.  Basal may be provided with long acting or intermediate acting or continuos infusion  Insulin for post prandial control-short acting(regular or analogue)  NPH-intermediate acting-category B  Detemir-long acting category B  Lispro,aspar ultra short acting-category B  Glargine-long acting-category C
  • 29. INSULIN THERAPY  NPH is usually started at 4 units and then titrated  If morning PP is more,regular insulin in morning  If predinner is high,night dose of rapid insulin  Mixed split regimen-total insulin requirement-2/3 in morning,1/3 night,of each dose 1/3 rapid and 2/3 intermediate acting.
  • 30. Insulin  ≈ 15% need insulin  Total dose varies. ≈ 0.7 to 2 units per kilogram (present pregnant weight)  FBG high – Night NPH ≈ 0.2 units/kg  PPBG high – bolus ≈ 1.5 units/10 gm CH2O for breakfast and ≈ 1 unit /10 gm CH2O for lunch and dinner  If both pre and postprandial BG high or if the woman's postprandial glucose levels can only be blunted if starvation ketosis occurs - four injection/day regimen.  Total 0.7 unit/kg up to week 18  0.8 unit/kg for weeks 18 to 26  0.9 unit/kg for weeks 26 to 36  1. unit/kg for weeks 36 to term.  In a morbidly obese woman, the initial doses of insulin may need to be increased to 1.5 to 2. units/kg to overcome the combined insulin resistance of pregnancy and obesity.
  • 31. Status of OHA in pregnancy  Metformin and the sulfonylurea glyburide are the 2 most commonly prescribed oral antihyperglycemic agents during pregnancy  Due to efficacy and safety concerns, the ADA and DIPSI does not recommend oral antihyperglycemic agents for gestational diabetes mellitus (GDM) or preexisting T2DM Medication Crosses Placenta Classification Notes Metformin Yes Category B Metformin and glyburide may be insufficient to maintain normoglycemia at all times, particularly during postprandial period Glyburide Minimal transfer Some formulations category B, others category C
  • 32. Fetal monitoring  USG:18-20 weeks,anomaly scan  Fetal ECHO:20-24 weeks  From 26 weeks,every 2-3 weeks-liquor volume  Abdominal circumference monitoring>70 indication of insulin  Chromosomal abnormalities,NTD
  • 33. Management Intrapartum  Attention to labor pattern, as cephalopelvic disproportion may indicate fetal macrosomia  If steroids or beta agonists used,increase insulin  Skip morning insulin on day of induction.  Usually no need of insulin while labour.  Hourly blood glucose monitoring during active labor, with insulin drip if necessary  Notify pediatrics if patient has poorly controlled blood sugars antepartum or intrapartum
  • 34. Management Postpartum  For patients with pregestational diabetes, halve dose of insulin and continue to check blood glucose in immediate postpartum period  For GDM patients who required insulin therapy (GDMA2), check fasting and postprandial blood sugars and treat with insulin as necessary  For GDM patients who were diet controlled (GDMA1), no further monitoring nor therapy is necessary immediately postpartum
  • 35.  Metformin and glyburide are secreted into breast milk and are therefore contraindicated during lactation  Breastfeeding plus insulin therapy may lead to severe hypoglycemia1  Greatest risk is in women with T1DM  Preventive measures are: reduce basal insulin dosage and/or carbohydrate intake prior to breastfeeding  For baby,start early breast feeding,CBG at 1 hour and 4 values in first 24 hours,before each feed.<44 is considered hypoglycemia.
  • 36. Management Postpartum  For all GDM patients, perform 75 gram 2-hour OGTT at 6 week postpartum visit to rule out pregestational diabetes  Most common recommendation is for primary care physician to repeat  2-hour OGTT every three years
  • 37. Who will progress to DM?  WC and BMI – stronset predictors  Autoantibodies  DM at earlier gestational age  Gestational requirement of insulin  Higher FBG  Higher BG on OGTT  Neonatal hypoglycemia  Recurrent GDM